Summit Investment Advisors Inc. Sells 186 Shares of Eli Lilly and Company $LLY

Summit Investment Advisors Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 0.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,198 shares of the company’s stock after selling 186 shares during the period. Eli Lilly and Company accounts for 13.7% of Summit Investment Advisors Inc.’s holdings, making the stock its 24th biggest holding. Summit Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $16,682,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LLY. Bensler LLC lifted its stake in Eli Lilly and Company by 5.5% in the 2nd quarter. Bensler LLC now owns 17,927 shares of the company’s stock worth $13,974,000 after purchasing an additional 934 shares in the last quarter. AE Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 8.9% in the second quarter. AE Wealth Management LLC now owns 68,235 shares of the company’s stock worth $53,193,000 after buying an additional 5,592 shares in the last quarter. Stokes Family Office LLC increased its stake in Eli Lilly and Company by 2.3% in the 2nd quarter. Stokes Family Office LLC now owns 4,208 shares of the company’s stock worth $3,280,000 after acquiring an additional 96 shares during the last quarter. Paradigm Asset Management Co. LLC raised its holdings in shares of Eli Lilly and Company by 200.0% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 1,050 shares of the company’s stock worth $819,000 after acquiring an additional 700 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $1,180,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 4,314 shares of company stock valued at $2,766,929 over the last 90 days. Company insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LLY. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Leerink Partners reiterated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Guggenheim reissued a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $960.88.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $923.35 on Friday. The company has a market cap of $872.92 billion, a P/E ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock’s 50-day moving average is $799.97 and its 200 day moving average is $775.76. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the business earned $1.18 EPS. The company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.